Total amount: € 0,00
Official Journal of the Italian Society of Dermatology and Sexually Transmitted Diseases
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,014
Vena G. A., Cassano N., Mastrolonardo M., Loconsole F., Coviello C., Arpaia N.
From the Università degli Studi di Bari - Bari, Istituto di Clinica Dermatologica
In the last 5 years we have verified the efficacy of a topical preparation (Lichtena® AI cream, UCB Pharma Italy) in various inflammatory skin diseases. Lichtena® AI cream contains 0.7% fural-glucitol, an antioxidant agent, along with other compounds provided with possible antiinflammatory and antioxidant properties.
In particular, the effects of the cream were evaluated in patients with the following skin disorders: irritant and allergic contact dermatitis (42 patients), atopic dermatitis (22 patients), seborrheic dermatitis of childhood and adulthood (18 and 106 cases, respectively), cutaneous lupus erythematosus (8 cases), photocontact dermatitis (2 cases), and actinic reticuloid (2 cases). All the patients were requested to apply twice daily a small amount of the cream to the lesional skin for a mean period of 8 weeks. The treatment gave good to excellent results in a relevant rate of cases in terms of both patients’ self-perceived response and objective improvement of cutaneous signs of the disease.
The results obtained in our and some others’ experiences indicate the feasibility of the cream as an alternative, steroid-sparing therapeutical tool. The exact mechanism of action of the preparation is not yet understood: it is likely that some active ingredients, possibly interacting each other with synergistic and potentiating effects, mediate the antiinflammatory action, and that, in this context, antioxidants play a relevant role.